who concerned about h5n1 x h1n1 mutation, page-2

The question in my mind is how big, GSK are ramping production, but is 200m doses per annum capacity enough? I would have thought the world needs a stockpile of around 50% population, once they have that then they can replensih with a lower production annually. In otherwords annual production should equal targeted stockpile divided by x (x = effective shelf life), but first you have to get to that target.

And then we have LANI, with so many advantages over current anti-virals I'm sure large pharma will be aggressively bidding for this, we'll seen soon enough.

I agree, it does look possible for the anti-viral market to grow from mega-blockbuster to Super-mega-blockbuster in coming years.